Ocuphire Pharma Investor Presentation Deck
Diabetic Retinopathy At a Glance
Current Treatment Landscape Demonstrates Need for Non Invasive Therapies
^^^^^^^
MM
There are ~8M adults in
the U.S. with NPDR
Ocuphire
PHARMA
The number of people with
DR expected to increase
more than 14M by 2050
22
Physicians have no non-invasive
options for NPDR with current
standard being wait-and-monitor
ta
Prevention of Progression is favored
by payors in chronic disease such as
diabetes which is the leading cost
driver
American Diabetes Association; International Diabetes Federation; Healthline; *Ocuphire internal analysis and assumptions;
Das UN. DME, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci. 2016;12(5):1142-1157. doi:10.5114/aoms.2016.61918
Patient survey adapted from Lions International Foundation and International Diabetes Foundation-Europe; Meltzer 2000
DR is the leading cause
of blindness among working-
age adults with the median
age of onset at 45 – 50 years
Majority of moderate to severe
patients with DR are not treated with
anti-VEGF due to injection burden
and no benefit to visual acuity
Guidehouse Triangulation of Global Data, Market Scope and Investor Forecasts (2020) AMD = Age-Related Macular Degeneration; DME = Diabetic Macular Edema; BRVO = Branch Retinal Vein Occlusion
National Center for Chronic Disease Prevention & Health Promotion. Health & economic costs of chronic diseases. Atlanta (GA): Centers for Disease Control & Prevention, US Department of Health and Human Services; 2018
Four-Year Visual Outcomes in a Randomized Trial of Intravitreous Aflibercept for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)." JAMA. February 7, 2023
7View entire presentation